Blood Screening Market Size, Share, Industry, Forecast and outlook (2026-2033)

Global Blood Screening Market is segmented By Product Type (Instruments  (Outright Purchase, Rental Purchase), Reagents & Kits (NAT Reagents & Kits, ELISA Reagents & Kits, Other Reagents),  Software and Services), By Technology (Next-Generation Sequencing, Nucleic Acid Test, Enzyme-Linked Immunosorbent Assay (ELISA, By Platform, ELISA, By Generation, Western Blot Assay, Rapid Tests, others)), By End-Users (Hospitals, Blood Banks, others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2026-2033

Last Updated: || Author: Akshay Reddy || Reviewed: Akshay Reddy || SKU: CD1618

Buy any syndicated report and get free complimentary customization of up to 20% of the Report and an interactive dashboard.

Report Summary
Table of Contents
List of Tables and Figures

Blood Screening Market Size

Global Blood Screening Market was valued at approximately US$2.72 billion in 2025 and is projected to reach US$4.78 billion by 2033, growing at a CAGR of 6.9% during 2026–2033.

Blood screening tests are performed to identify infection signs in order to stop the distribution of contaminated blood and blood components for clinical use. A blood screening test is done to detect potential health disorders or diseases in people who do not have any symptoms of the disease.

Blood screening strategies are designed to assure the safety of blood units, but should not be used for notifying blood donors of reactive test results. Various technologies are used in blood screening tests which include next-generation sequencing, nucleic acid tests, and ELISA.

 

Market Summary

MetricsDetails
CAGR6.9%
Market Size Available for Years2025-2033
Market Estimation Forecast Period2026-2033
Revenue UnitsValue (US$ Mn) 
Segments CoveredProduct Type, Technology, End Users
Regions CoveredNorth America, Europe, Asia-Pacific, South America, and Middle East & Africa
Largest RegionNorth America
Fastest Growing RegionAsia-Pacific
Report Insights CoveredCompetitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.

 

For more details on this report Request for Sample

 

Market Dynamics

Increasing launches of blood screening tests

Blood screening tests are performed on a blood sample to provide valuable information and diagnose specific medical conditions. The increasing number of product launches for blood screening tests acts as a significant driver for market growth. Also, many significant companies play a major role in the advancements of the market by launching new blood screening tests and kits.

For instance, in October 2023, Delfi Diagnostics launched a blood-based lung cancer screening test. It aims to provide a more convenient detection method and one that’s capable of reaching a greater number of people than the current standard.

Additionally, in August 2023, Quest Diagnostics introduced its AD-Detect test for Alzheimer’s disease in the United States by making it the first blood-based biomarker test available for consumers to purchase and assess the potential risks of developing Alzheimer’s disease.

Furthermore, the global blood screening market is driven by various factors like rising blood donations, and an increase in the incidence of infectious diseases is expected to drive the market in the forecast period.

The stringent regulatory approvals and high cost of blood screening equipment

Stringent regulatory requirements can slow the approval and adoption of new blood screening technologies or tests. Also, the high cost associated with blood screening equipment can hamper the market growth. 

Market Segment Analysis

The global blood screening market is segmented based on product type, technology, end users, and region.

Reagents and kits accounted for approximately 48.4% of the market share 

The anti-A, anti-B, and anti-A, B reagents are used in the red blood cell determination of the ABO blood group. They are used to determine the absence or presence of erythrocytic antigens A or B on the surface of human red blood cells. Reagents and kits are expected to hold the largest market share over the period forecast owing to the high requirement for reagents, kits, and product launches. 

For instance, in June 2023, Sysmex launched an assay kit to identify Amyloid Beta (Aβ) accumulation in the brain that causes  Alzheimer’s disease by using a small amount of blood. 

Additionally, in July 2021, Ortho Clinical Diagnostics launched its VITROS Immunodiagnostic Products IL-6 Reagent Pack which is the latest addition to Ortho's VITROS Critical Care blood screening menu.

Market Geographical Share

North America is expected to hold a significant position in the global blood screening market share

The global blood screening market is segmented into North America, Europe, Asia Pacific, South America, Middle East, and Africa. 

North America has maintained a significant market proportion due to factors such as the rising blood transfusion rates, and product launches, this trend is anticipated to continue throughout the forecast period.

For instance, according to the American Red Cross, in the United States, an estimated 10,000 units of plasma, roughly 7,000 units of platelets, and 36,000 units of red blood cells are needed per day. In the United States, more than 21 million blood components are transfused annually.

Additionally, in September 2023, Oxford BioDynamics, Plc. launched its 94% accurate EpiSwitch prostate screening blood test for men with prostate cancer risk. 

Market Competitive Landscape

The major global players in the market include Bio-Rad Laboratories, Inc., Grifols S.A, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomérieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson, and Company, Beckman Coulter (Danaher Corporation). among others.

Key Developments

  • November 2026: U.S. FDA – Updated Guidance for Hepatitis B Blood Screening

    The U.S. FDA issued its final industry guidance, Recommendations for Reducing the Risk of Transfusion-Transmitted Hepatitis B Virus, in November 2026. The guidance provides recommendations for HBV testing of whole blood, blood components, and source plasma, emphasizing the use of FDA-licensed, approved, or cleared screening tests. This development reinforces regulatory requirements for identifying HBV infections and reducing transfusion-related transmission risks.

  • October 2026: U.S. FDA – Updated Blood Donor Eligibility and Screening Compliance Policies

    The U.S. FDA issued updated compliance policies concerning blood and blood component donation suitability, donor eligibility, and source plasma quarantine requirements in October 2026. These regulatory updates reinforce the importance of standardized donor assessment, screening procedures, and blood product management to maintain transfusion safety and regulatory compliance across blood collection establishments.

  • June 2026: World Health Organization – Global Blood Safety and Availability Report

    The World Health Organization published its Global Status Report on Blood Safety and Availability 2025 on June 12, 2026, drawing on information from 168 countries. The report assessed national blood collection systems, laboratory screening for transfusion-transmissible infections, quality assurance, haemovigilance, and blood product availability. It highlighted persistent gaps in blood safety and access, particularly across low- and middle-income countries, reinforcing the need for stronger screening infrastructure and standardized testing practices.

  • July 2026: SensTek Diagnostics – Development of Multi-Pathogen Blood Screening Platform

    SensTek Diagnostics advanced pre-clinical validation of its multi-target pathogen screening platform for potential blood safety applications. The evaluation, involving independent testing by the American Red Cross Scientific Support Office, focuses on detecting transfusion-transmissible pathogens, including syphilis, West Nile virus, Trypanosoma cruzi, and Babesia species. The initiative reflects growing interest in multiplex molecular screening for detecting a broader range of infectious threats in donated blood.

  • July 2026: GFE – Launch of PoET Multiscreen PCR Kit

    GFE announced the launch of its PoET Multiscreen PCR kit for blood donation screening after receiving In Vitro Diagnostic Regulation (IVDR) certification. The assay enables simultaneous detection and differentiation of hepatitis C, hepatitis B, and HIV, supporting multiplex molecular screening and more efficient testing workflows for blood donation laboratories.

  • June 2026: Canadian Blood Services – Submission for Malaria NAT Screening

    Canadian Blood Services submitted a regulatory application to Health Canada on June 11, 2026, seeking approval to introduce malaria NAT into its blood donor screening process. The proposed test can detect very low levels of malaria parasites and could reduce donation waiting periods for individuals previously excluded because of malaria exposure. The initiative also aims to expand donor participation and improve blood availability for patients requiring regular transfusions.

 

Why Purchase the Report?

  • To visualize the global blood screening market segmentation based on product type, technology, end users and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of blood screening market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global blood screening market report would provide approximately 61 tables, 58 figures, and 185 Pages.

Target Audience 

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies
Save 31% on all licenses
Single User$4350$2999Corporate$7850$5412

Free 20% customization + dashboard

Trusted by Global Leaders

ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
FAQ’s

  • Key players are Bio-Rad Laboratories, Inc., Grifols S.A, Abbott Laboratories, F. Hoffmann-La Roche, Siemens Healthineers, Biomérieux, Thermo Fisher Scientific, Inc., Ortho Clinical Diagnostics, Inc., Becton, Dickinson, and Company, Beckman Coulter (Danaher Corporation).

  • North America is expected to hold a significant position in the global blood screening market share.
PDF
DataM
Blood Screening Market Report
SKU: CD1618

Data-Backed Decisions Start Here

Explore how our research empowers industry leaders to cut through uncertainty. Get a free sample of this report or tailor it precisely to your business needs.

ISO 27001 Certified
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
ADM
Africa Climate Ventures
Algalif
Amcor
Arysta
Asahi
BASF
Baycurrent
BAYER
BioCartis
BIORAD
BRAUN
Budenheim
Daikin
Deerland
DENSO
DUPONT
Epax
FrieslandCampina
FUJIFILM
Hitachi
HONDA
HUAWEI
Inorganic Ventures
ITOCHU
JFE Steel
KAMEDA
Kaneka
KERRY
Marubeni
Meiji
Mitsubishi
MITSUI & Co
Morinaga
NFIT
NIPRO
Pfizer
Plexus
Polaris
Probiotical
RKW
Kearney
Takeda
Sensia
SACCO system
SEKISUI
SKYTILLER
Sony
Sumitomo Chemical
Symrise
Tate & Lyle
Teijin
thyssenkrupp
TORAY
TOSHIBA
Unilever
Xerox
Related Reports